Remarkably, TGFβ signaling can also be blocked through angiotensin receptor inhibitors (ARB), such as losartan, which enhanced delivery of chemotherapy and improved overall survival in BrCa models [178]. Here, TGFB1 is linked to invasive breast carcinoma.